Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes
Autor: | Akvile Statnickaite, Kristina Jureniene, Jorune Suipyte, Sigita Liutkauskiene, Elona Juozaityte, Saulius Grizas |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Cyclophosphamide Anthracycline Molecular subtypes medicine.medical_treatment Breast Neoplasms Kaplan-Meier Estimate Neutropenia lcsh:RC254-282 Time-to-Treatment 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols Genetics Medicine Humans Doxorubicin Anthracyclines Overall survival 030212 general & internal medicine Neoplasm Staging Proportional Hazards Models Retrospective Studies Chemotherapy Chemotherapy scheme modifications business.industry medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens AC Regimen Combined Modality Therapy Regimen Treatment Outcome 030220 oncology & carcinogenesis Female Neoplasm Grading business medicine.drug Research Article |
Zdroj: | BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018) BMC Cancer |
ISSN: | 1471-2407 |
Popis: | Background The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracycline modification effects and to analyze reasons for such chemotherapy scheme modifications. Methods Medical records of patients with stage I-III breast cancer were reviewed. Inclusion criteria involved stage I- III breast carcinoma; radical surgery performed and 4 courses of AC regimen (doxorubicin and cyclophosphamide), or at least 6 courses of FAC regimen (fluorouracil, doxorubicin and cyclophosphamide) completed; no neoadjuvant chemotherapy applied; no taxane group medications administered; medical records maintain comprehensive data on treatment and follow-up. 5- year overall survival were analyzed using Kaplan-Meier and Cox proportional hazards models. Results Significant 3.17 times higher death risk at 5 year period in patients who experienced anthracycline dose reduction compared with patients who did not experience any modifications was established (HR = 3.17, 95% CI 1.7–5.9, p |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |